Neuraxis Inc (NRXS) Stock Price, Quote & News

Company Profile

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly kno...

Industry: Biotechnology

Sector: Healthcare

Phone: 812 689 0791

Website: neuraxis.com

Address:

11611 North Meridian St, Suite 330, Carmel, United States

alexpitti Nov. 21 at 12:32 AM

$NRXS

0 · Reply

alexpitti Nov. 20 at 11:46 PM

there's simple no chance the ceo would claim I didn't video call with him. yes I did email him AND video call. both can be true. if he does, that could justify shorting the stock $NRXS

0 · Reply

alexpitti Nov. 20 at 10:39 PM

$NRXS it makes no logical sense for a cpt code to make insurers pay for a device. Rather insurers need evidence that it works long term. Paying $5 k for a device that is only proven to work 9 weeks is not going to work. It's very simple. Prove it works for 1 year with a placebo controlled study. Open label doesn't tell us much for this type of problem. It's basic stuff.

0 · Reply

alexpitti Nov. 20 at 8:02 PM

$NRXS there is no long term placebo controlled trial. A cpt code can't get insurance coverage

0 · Reply

S144 Nov. 19 at 4:21 PM

$NRXS +4.58% today. $2.51. So it is great to see it is climbing up again .. The worst days are over .. @alexpitti

1 · Reply

ZacksResearch Nov. 17 at 6:07 PM

$NRXS down 36.4% over the past month — what's behind the plunge? 📉 Despite a 21.7% revenue rise in Q3, NeurAxis reported a wider operating loss of $2.1M due to selling expenses rising 125.3% YoY. The stock's struggle continues, but a new CPT code in 2026 is expected to streamline billing and reduce administrative hurdles. ⚠️ Full breakdown here 👉 https://www.zacks.com/stock/news/2792114/nrxs-stock-declines-post-q3-earnings-despite-continued-revenue-growth?cid=sm-stocktwits-2-2792114-body-21337&ADID=SYND_STOCKTWITS_TWEET_2_2792114_BODY_21337

0 · Reply

ZacksResearch Nov. 17 at 5:07 PM

$NRXS sliding after Q3 — and the pressure is coming from more than the headline suggests. Even with a fifth straight quarter of double-digit expansion, rising costs and margin compression are hitting the latest 2025 results hard, and the stock’s reflecting it. ⚠️ See what’s driving the weakness here 👉 https://www.zacks.com/stock/news/2792114/nrxs-stock-declines-post-q3-earnings-despite-continued-revenue-growth?cid=sm-stocktwits-2-2792114-teaser-21314&ADID=SYND_STOCKTWITS_TWEET_2_2792114_TEASER_21314

0 · Reply

S144 Nov. 16 at 9:50 PM

$NRXS NeurAxis Negative Information Hot Off the Press and Regurgitated https://microcapopportunities.substack.com/p/neuraxis-negative-information-hot

0 · Reply

alexpitti Nov. 13 at 5:45 PM

I sold my $NRXS at $2.81 and $AUTL at $1.61 a couple weeks ago. I sold Neuraxis because I'm concerned with the lack of a long term double blind study. 9 weeks is not enough for the payors to get involved. This only works if there are long term effects. The long term data is not double blind. I sold Autolus because my broker eliminated Abeona as margininable and something had to go.

2 · Reply

JcCapital Nov. 12 at 2:32 PM

$NRXS back to $ 3

0 · Reply

NeurAxis, Inc. (NRXS) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 7:00 AM EST - 23 days ago

NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues

Aug 12, 2025, 12:29 PM EDT - 4 months ago

NeurAxis, Inc. (NRXS) Q2 2025 Earnings Call Transcript

Jun 17, 2025, 8:00 AM EDT - 6 months ago

NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives

May 22, 2025, 1:03 PM EDT - 7 months ago

NeurAxis Announces Closing of $5.0 Million Registered Direct Offering

May 21, 2025, 7:00 AM EDT - 7 months ago

NeurAxis Announces $5.0 Million Registered Direct Offering

May 12, 2025, 1:58 PM EDT - 7 months ago

NeurAxis, Inc. (NRXS) Q1 2025 Earnings Call Transcript

May 12, 2025, 8:15 AM EDT - 7 months ago

NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

May 5, 2025, 9:00 AM EDT - 7 months ago

NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

Mar 20, 2025, 4:18 PM EDT - 9 months ago

NeurAxis, Inc. (NRXS) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 8:15 AM EDT - 9 months ago

NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues

Mar 12, 2025, 9:00 AM EDT - 9 months ago

NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025

Jan 21, 2025, 1:45 PM EST - 11 months ago

UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States

Jan 21, 2025, 9:00 AM EST - 11 months ago

NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States

Jan 13, 2025, 9:00 AM EST - 11 months ago

NeurAxis Inc. Issues Letter to Shareholders

Jan 6, 2025, 9:00 AM EST - 11 months ago

NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Nov 15, 2024, 2:04 PM EST - 1 year ago

NeurAxis, Inc (NRXS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:10 AM EST - 1 year ago

NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

Oct 22, 2024, 9:00 AM EDT - 1 year ago

NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation

Sep 19, 2024, 9:00 AM EDT - 1 year ago

NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Aug 27, 2024, 9:00 AM EDT - 1 year ago

NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024

Aug 13, 2024, 9:00 AM EDT - 1 year ago

NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024

Aug 11, 2024, 5:44 AM EDT - 1 year ago

NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 8:00 AM EDT - 1 year ago

NeurAxis Reports Second Quarter 2024 Financial Results

Jun 7, 2024, 9:00 AM EDT - 1 year ago

NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure

May 22, 2024, 1:34 PM EDT - 1 year ago

NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript

May 22, 2024, 8:00 AM EDT - 1 year ago

NeurAxis Reports First Quarter 2024 Financial Results

May 21, 2024, 9:00 AM EDT - 1 year ago

NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 15, 2024, 4:30 PM EDT - 1 year ago

NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024

Apr 23, 2024, 9:00 AM EDT - 1 year ago

NeurAxis Announces New Medical Policy Coverage in North Dakota

Apr 9, 2024, 6:45 PM EDT - 1 year ago

NeurAxis, Inc. (NRXS) Q4 2023 Earnings Call Transcript

Apr 9, 2024, 4:05 PM EDT - 1 year ago

NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Apr 1, 2024, 4:15 PM EDT - 1 year ago

NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024

Mar 27, 2024, 9:00 AM EDT - 1 year ago

NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry

Mar 11, 2024, 9:00 AM EDT - 1 year ago

NeurAxis Announces Highmark BCBS Policy Coverage

Mar 4, 2024, 9:00 AM EST - 1 year ago

NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage

Feb 27, 2024, 11:00 AM EST - 1 year ago

NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Jan 31, 2024, 9:00 AM EST - 2 years ago

NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

Dec 20, 2023, 9:00 AM EST - 2 years ago

NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer

Nov 20, 2023, 5:30 PM EST - 2 years ago

NeurAxis Reports Third Quarter 2023 Financial Results

Nov 15, 2023, 9:00 AM EST - 2 years ago

NeurAxis Announces CareFirst BCBS Policy Coverage

Nov 14, 2023, 9:00 AM EST - 2 years ago

NeurAxis Secures $3 Million Financing

Nov 8, 2023, 9:00 AM EST - 2 years ago

NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device

Sep 21, 2023, 8:00 AM EDT - 2 years ago

NeurAxis Reports Second Quarter 2023 Financial Results

Sep 13, 2023, 9:00 AM EDT - 2 years ago

NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase

Sep 12, 2023, 9:00 AM EDT - 2 years ago

NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS

Aug 29, 2023, 9:00 AM EDT - 2 years ago

NeurAxis Highlights Pediatric Post-Concussion Clinical Study

Aug 24, 2023, 9:00 AM EDT - 2 years ago

NeurAxis Highlights Strength of its Board of Directors

Aug 22, 2023, 9:00 AM EDT - 2 years ago

NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome

Aug 17, 2023, 9:02 AM EDT - 2 years ago

NeurAxis Announces Over $8 Million in IB-Stim™ Revenue

alexpitti Nov. 21 at 12:32 AM

$NRXS

0 · Reply

alexpitti Nov. 20 at 11:46 PM

there's simple no chance the ceo would claim I didn't video call with him. yes I did email him AND video call. both can be true. if he does, that could justify shorting the stock $NRXS

0 · Reply

alexpitti Nov. 20 at 10:39 PM

0 · Reply

alexpitti Nov. 20 at 8:02 PM

$NRXS there is no long term placebo controlled trial. A cpt code can't get insurance coverage

0 · Reply

S144 Nov. 19 at 4:21 PM

$NRXS +4.58% today. $2.51. So it is great to see it is climbing up again .. The worst days are over .. @alexpitti

1 · Reply

ZacksResearch Nov. 17 at 6:07 PM

0 · Reply

ZacksResearch Nov. 17 at 5:07 PM

0 · Reply

S144 Nov. 16 at 9:50 PM

$NRXS NeurAxis Negative Information Hot Off the Press and Regurgitated https://microcapopportunities.substack.com/p/neuraxis-negative-information-hot

0 · Reply

alexpitti Nov. 13 at 5:45 PM

2 · Reply

JcCapital Nov. 12 at 2:32 PM

$NRXS back to $ 3

0 · Reply

Tennis_4567 Nov. 12 at 2:21 PM

$NRXS <@898226711160832000> https://ir.neuraxis.com/news-releases/news-release-details/neuraxis-announces-new-medical-policy-coverage-michigan-adding

0 · Reply

S144 Nov. 11 at 6:59 PM

$NRXS Anyway, it is good they already sold $2.8M comparing to the situation if they didn't sell anything by now. So they are halfway with selling ..

0 · Reply

S144 Nov. 11 at 5:53 PM

$NRXS They say they raised $2.8M in October, but they are required to disclose withing 4 days when they start selling new shares. I haven't seen that disclosure .. So what is going on here ? @alexpitti

1 · Reply

S144 Nov. 11 at 4:03 PM

$NRXS Q3 results: "Cash on hand as of September 30, 2025, was $4.4 million. In October 2025, the Company improved its liquidity position by raising $2.8 million through an at-the-market common stock offering and the exercises of warrants." So they were selling the new shares in October and probably that put pressue on the share price .. Remember: the problem with share price started on 10/24/25 when the released the news about FDA approval. So I am wondering: did they start selling the new shares from that day ? However CEO indicated they were not selling the new shares on that day .. But on that day there was a huge trading volume. So when were they selling ? There is some mystery about it . WTF is going on ? @alexpitti

0 · Reply

alexpitti Nov. 11 at 3:49 PM

sorry. i was wrong. $NRXS did hit the atm near the high

1 · Reply

S144 Nov. 11 at 7:27 AM

$NRXS Today: NRXS results, before market opens: https://ir.neuraxis.com/news-releases/news-release-details/neuraxis-host-third-quarter-2025-results-and-business-update webast link: https://ir.neuraxis.com/events/event-details/neuraxis-third-quarter-2025-earnings-conference-call

0 · Reply

shortistmord Nov. 7 at 5:53 PM

$NRXS first Cigna, now Blue Shield of California with a negative annual review. Yes, it is still the old CPT code, but this is another disappointment nonetheless. The company guided to 100M covered lives by year end and that guidance is obviously based on the current CPT Code. There is no positive spin on this. https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Perc-Electrical-Nerve-Field-Stim-Irritable-Bowel-Syndrome.pdf

0 · Reply

JcCapital Nov. 6 at 7:57 PM

$NRXS no volume ...this needs to be pumped

0 · Reply

S144 Nov. 5 at 7:30 AM

$NRXS The big sell off continues after good news 1.5 week ago. $2.46 after hours .. WTF is going on ?

1 · Reply

S144 Nov. 1 at 8:13 AM

$NRXS I was just reading trying to better understand how the process of raising money using ATM works. So right now I am conviced NRXS hasn't issued and sold any new shares. Official SEC Rule: Form 8-K File within 4 business days of: - The first ATM sale, OR - A material sale (e.g., >5% of float, >$1M, etc.)

0 · Reply

S144 Nov. 1 at 4:54 AM

$NRXS I have seens the news: "NeurAxis Expands Stock Offering to $6.27 Million" NeurAxis increased its stock offering to $6.27 million but sold no shares by October 23, 2025. https://www.tipranks.com/news/company-announcements/neuraxis-expands-stock-offering-to-6-27-million The main question I have is: have they raised that money yet or not ? @alexpitti

0 · Reply

JcCapital Oct. 31 at 6:57 PM

$NRXS we need more volume

1 · Reply

Market Cap	28.55M
Revenue (ttm)	2.69M
Net Income (ttm)	-8.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-306.32%
Debt to Equity Ratio	0.00

Volume	38,134
Avg Vol	477,932
Day's Range	N/A - N/A
Shares Out	10.65M
Stochastic %K	92%
Beta	3.13
Analysts	Strong Sell
Price Target	$7.00